APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.

APR Applied Pharma Research s.a. ("APR") announces participation to the Biotech Showcase 2011 Annual Conference in San Francisco scheduled for January 10-12, 2011

APR Applied Pharma Research ("APR") and Labtec GmbH ("Labtec") announce filing for approval in Europe of Zolmitriptan Oral Dispersible Film (ODF)

APR appoints Director of Corporate Development

APR Applied Pharma Research s.a. ("APR") and Labtec GmbH Enter Into Exclusive Licensing Agreement With Ferrer Internacional for the Registration and Marketing of Donepezil Oral Dispersible Film in Spain, Portugal and Germany

LABORATORIOS CINFA launches Respirub in Spain, an innovative formulation of a balsamic rub cream, also available in pediatric formulation, developed by APR Applied Pharma Research.

APR Applied Pharma Research ("APR") and Labtec GmbH ("Labtec") announce the successful completion of the pivotal clinical study on Zolmitriptan RapidFilm©, and its upcoming submission for registration in Europe.

Nautilus Neurosciences and APR Applied Pharma Research s.a. Announce Extension of Patent Protection for CAMBIA™
(diclofenac potassium for oral solution) through 2026

MonoSol Rx Announces FDA Approval of Zuplenz® Oral Soluble Film for Treatment of Nausea and Vomiting

APR Applied Pharma Research s.a. of Switzerland launches its new corporate website and announces key strategic changes in its Business Model to better compete in the rapidly changing Healthcare industry

MonoSol Rx and APR Applied Pharma Research s.a. Expand Joint Collaboration Agreement to develop and commercialize film formulations of prescription products

Nautilus Neurosciences Announces U.S. Launch of CAMBIA™ (Diclofenac Potassium for Oral Solution) for the Treatment of Migraine

Galen Partners Invests in Nautilus Neurosciences, Inc.

Funding to Provide Growth Capital for the Launch of CAMBIA(TM)

APR Applied Pharma Research s.a. ("APR") and Labtec GmbH ("Labtec") announce the European Approval of Ondansetron RapidFilm™

APR Applied Pharma Research SA., together with its joint venture partner Labtec GmbH, announces the signature of an exclusive licensing agreement with SciClone Pharmaceuticals, Inc. for Ondansetron RapidFilm™ for China and Vietnam

Abdi Ibrahim Pharmaceuticals ("Abdi Ibrahim") and APR Applied Pharma Research SA ("APR"), together with its joint venture partner Labtec GmbH ("Labtec"), today announced that they have entered into an exclusive licensing agreement under which Abdi Ibrahim has the exclusive rights to market Ondansetron Rapidfilm® in Turkey.

FDA has approved Cambia™, Potassium Diclofenac Powder for Oral Solution for the treatment of acute migraine attacks with or without aura, originally developed by APR Applied Pharma Research SA (APR) using the patented Dynamic Buffering Technology (DBT).

APR acquires a new Drug Delivery Nanotechnology Platform providing innovative treatment solutions for critical diseases

BioAlliance Pharma Files for European Marketing Authorization for Ondansetron RapidFilm in Supportive Care in Cancer

APR and Fidia have received IND approval from FDA for a new NSAID Matrix Patch product

APR Applied Pharma Research SA., together with its joint venture partner Labtec GmbH, announces the signature of an exclusive licensing agreement with BioAlliance Pharma SA. for Ondansetron RapidFilm™ for Europe

APR Applied Pharma Research s.a. ("APR") launches its new website to communicate its corporate identity.

APR Applied Pharma Research s.a. ("APR") and Labtec GmbH ("Labtec") announce the successful completion of the pilot bioequivalence study of their Donepezil RapidFilm™ further confirming the validity and adaptability of this innovative proprietary technology.

APR Applied Pharma Research s.a. ("APR") and Labtec GmbH ("Labtec") announce the successful completion of the Pivotal Bioequivalence study for their proprietary Ondansetron RapidFilm™

APR Applied Pharma Research s.a. opens US office in Charlotte, North Carolina

APR Applied Pharma Research s.a. announces a New Drug Application has been initiated for its Immediate Release Diclofenac-K 50mg Sachet for Migraine by its US licensee ProEthic Pharmaceuticals Inc.

SANOFI-AVENTIS launches in the Belgian Market an innovative balsamic decongestant cream for Cough & Cold developed by APR Applied Pharma Research SA.

APR Applied Pharma Research s.a. and Labtec GmbH announce positive results of the Ondansetron RapidFilm™ pilot bioequivalence study. Submission of registration dossier anticipated for Q4/2007

APR Applied Pharma Research s.a. has successfully completed the development of Veloderm, an innovative biotech wound dressing and transferred the worldwide marketing rights to Medestea Internazionale.

APR announces Successful US Phase III Trial results for its original migraine product

APR Applied Pharma Research s.a.("APR") and Labtec GmbH ("Labtec) have signed a new strategic Partnership for the Development and Licensing of the RapidFilm (TM) Drug Delivery Technology

Swiss Drug Delivery Firm Licenses Fast-Acting Diclofenac Products to U.S. Based ProEthic Pharmaceuticals

Endo Licenses Topical Ketoprofen Patch for US and Canada

APR Applied Pharma Research SA and Novartis Pharma AG have signed a global license agreement, following successful clinical trials programme, for use of APR's quick release diclofenac delivery system.

APR Applied Pharma Research and ProEthic sign licensing agreement for the marketing of a Ketoprofen Patch in USA

European Patent granted to APR Drug Delivery Technology for the preparation of granulates for stable aqueous dispersions of hydrophobic substances.

European Patent granted for APR Imemdiate Release Technology

Cold Fleece Patch successfully launched in the major European Countries

APR has filed a new patent application for the preparation of stable aqueous dispersions of Hydrophobic substances, particularly Megestrol Acetate for the treatment of cachexia in patients with AIDS

APR has submitted for registration the Diclofenac K 5% Oral Drops File in The Netherlands

Partnership Agreement between Labtec GmbH and APR for a new NSAID Patch

APR announces launch of 50mg diclofenac potassium sachet formulation in Italy by Novartis Farma S.p.A.

The first technology for immediate, bioregulated release of diclofenac in new pharmaceutical forms